These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19017829)

  • 21. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
    Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
    Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Warfarin resistance.
    Sinxadi P; Blockman M
    Cardiovasc J Afr; 2008; 19(4):215-7. PubMed ID: 18776969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitosan potentiation of warfarin effect.
    Huang SS; Sung SH; Chiang CE
    Ann Pharmacother; 2007 Nov; 41(11):1912-4. PubMed ID: 17925502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Warfarin and celecoxib interaction.
    Mersfelder TL; Stewart LR
    Ann Pharmacother; 2000 Mar; 34(3):325-7. PubMed ID: 10917378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential interaction between telithromycin and warfarin.
    Kolilekas L; Anagnostopoulos GK; Lampaditis I; Eleftheriadis I
    Ann Pharmacother; 2004 Sep; 38(9):1424-7. PubMed ID: 15280511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.
    Muszkat M; Bialer O; Blotnick S; Adar L; Xie HG; Ufer M; Cascorbi I; Caraco Y
    Clin Ther; 2010 Feb; 32(2):347-56. PubMed ID: 20206792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bosentan and warfarin interaction.
    Murphey LM; Hood EH
    Ann Pharmacother; 2003; 37(7-8):1028-31. PubMed ID: 12841813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
    Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
    Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
    Siddiqi A; Khan DA; Khan FA; Naveed AK
    Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.
    Sconce EA; Kamali F
    Eur J Haematol; 2006 Dec; 77(6):457-62. PubMed ID: 17042764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients.
    Michaud V; Vanier MC; Brouillette D; Roy D; Verret L; Noel N; Taillon I; O'Hara G; Gossard D; Champagne M; Goodman K; Renaud Y; Brown A; Phillips M; Ajami AM; Turgeon J
    Clin Pharmacol Ther; 2008 May; 83(5):740-8. PubMed ID: 18030307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A probable interaction between warfarin and the antiretroviral TRIO study regimen.
    Liedtke MD; Vanguri A; Rathbun RC
    Ann Pharmacother; 2012 Nov; 46(11):e34. PubMed ID: 23115227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
    van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
    Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 37. Probable drug interaction between warfarin and hormonal contraceptives.
    Zingone MM; Guirguis AB; Airee A; Cobb D
    Ann Pharmacother; 2009 Dec; 43(12):2096-102. PubMed ID: 19934391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probable interaction between warfarin and bee pollen.
    Hurren KM; Lewis CL
    Am J Health Syst Pharm; 2010 Dec; 67(23):2034-7. PubMed ID: 21098375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critically elevated INR in a patient on warfarin after increase in extended-release niacin dose.
    Christopher A
    Ann Pharmacother; 2011 Nov; 45(11):e58. PubMed ID: 22010004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.